综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語(yǔ)Fran?ais
Business
Home / Business / The Second China International Import Expo

Novo Nordisk introduces new products at CIIE

By Liu Zhihua | chinadaily.com.cn | Updated: 2019-11-08 13:44
Share
Share - WeChat
Denmark's biopharmaceutical company Novo Nordisk has brought a much broader portfolio of healthcare solutions with more Chinese characteristics this year to the CIIE. [Photo provided to chinadaily.com.cn]

Thanks to the continued optimization of the local business environment and the opportunities generated during the deepening of the healthcare reform, Novo Nordisk has made significant progress over the past year in China, and aims to change diabetes for "Healthy China" through showcasing its innovative medicine products at the second China International Import Expo, a senior executive of the Denmark biopharmaceutical company said on Wednesday.

The company's booth at the CIIE 2019 is about 500 square meters, twice of last year. Its INNOVO open innovation platform, digital chronic disease management solution and the "Cities Changing Diabetes" program are all showcased at the CIIE as new attempts over the past few years to expand its industry model and join forces with all parties to address the challenges of diabetes and other metabolic diseases.

Christine Zhou, senior vice-president of the company and president of its China branch, said Novo Nordisk has brought a much broader portfolio of healthcare solutions with more Chinese characteristics this year to CIIE.

China's healthcare reform has been accelerated over the past few years, and Novo Nordisk is not only an observer of the fast development of medical care industry in China but also a beneficiary and a promoter of it, she said.

With the reform of China's new drug review system kicking off in 2015, a slew of the company's new generation basal insulin drugs and injection devices have been approved in China through fast-track path, or are included in the National Reimbursement Drug List, according to her.

Novo Nordisk has also shared its impressive array of achievements from its 25 years' presence in China, including a full range of high-quality therapeutic product portfolio, substantial R&D pipeline, leading-edge global research findings, global digital health care solutions, and the remarkable accomplishments of the Cities Changing Diabetes.

"International exchange and economic and trade cooperation are helping China to develop an open economic development landscape that is very substantial, highly productive and benefiting all the population," Zhou said.

"Through platforms like the CIIE, China is opening up its market to the world while constantly driving the growth of an open global economy – which is an important opportunity for multinational pharmaceutical companies and all other foreign-invested enterprises.

"Novo Nordisk will continue to drive the cause of Changing Diabetes in China and support its Healthy China 2030 vision through innovation and cooperation."

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
丹巴县| 裕民县| 涟水县| 宜丰县| 兴隆县| 天津市| 昌图县| 长泰县| 镇江市| 陕西省| 麻江县| 义马市| 阳谷县| 海口市| 西华县| 平罗县| 邵阳市| 澳门| 天峻县| 南充市| 永康市| 洪雅县| 通辽市| 金川县| 合川市| 来凤县| 武山县| 大关县| 富顺县| 兴化市| 玛多县| 渑池县| 广丰县| 南和县| 五华县| 涟水县| 西和县| 固原市| 叶城县| 玉屏| 宿州市|